Zusammenfassung
Betarezeptorenblocker hemmen die Funktion des sympathischen Nervensystems in allen Organen, die mit adrenergen Betarezeptoren (β1-/β2-) ausgestattet sind. Dazu gehören insbesondere das Herz, die Nieren und die glatte Muskulatur von Bronchien und Muskelgefäßen. Therapeutisch bedeutsam sind die Senkung der Herzfrequenz, des kardialen Sauerstoffverbrauchs, der Reninausschüttung aus der Niere und die Erniedrigung des Augeninnendrucks (Kapitel 38).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Aursnes I, Osnes J-B, Tvede IF, Gasemyr J, Natvig B (2007): Does atenolol differ from other ß-adrenergic blockers? BMC Clin Pharmacol 7:4
Arzneimittelkommission der deutschen Ärzteschaft (2009): 23. Arterielle Hypertonie: Arzneiverordnungen. 22. Aufl., Medizinische Medien Informations GmbH, Neu-Isenburg: S 597–628
Barron AJ, Zaman N, Cole GD, Wensel R, Okonko DO, Francis DP (2013): Sytematic review of genuine versus spurious side-effects of beta-blockers in heart failure using placebo control: recommendations for patient information. Int J Cardiol 168: 3572–3579
Beevers DG (2005): The end of beta blockers for uncomplicated hypertension? Lancet 366: 1510–1512
Bowman AJ, Chen CP, Ford GA (1994): Nitric oxide mediated venodilator effects of nebivolol. Brit J Clin Pharmacol 38: 199–204
Chatterjee S, Biondi-Zoccai G, Abbate A, D’Ascenzo F, Castagno D, Van Tassell B, Mukherjee D, Lichstein E (2013): Benefits of β blockers in patients with heart failure and reduced ejection fraction: network metaanalysis. BMJ 346: f596
Chobanian AV, et al (2003): Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute;. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC7). JAMA 289: 2560–72. Erratum in: JAMA 2003, 920:197
CIBIS II Study (1999): The cardiac insufficiency bisoprolol study II (CIBIS II): a randomised trial. Lancet 353: 9–13
Deutsche Gesellschaft für Kardiologie – Deutsche Hochdruckliga – European Society of Cardiology – European Society of Hypertension (2013): Leitlinien für das Mangement der arteriellen Hypertonie: www.escardio/org-guidelines, www.dgk.org, www.hochdruckliga.de; Europ Heart J 2013: 34:2159-2219; https://doi.org/10.1093/euroheartj/eht151
DiNIcolantonio JJ, Fares H, Niazi AK, et al. (2015): ß-Blockers in hypertension, diabetes, heart failure and acute myocardial infarction: a review of the literature. Open Heart 21(1): e000230
Du Q, Sun Y, Ding N, Lu L, Chen Y (2014): Beta-blockers reducde the risk of mortality and exacerbation in patients with COPD: a meta-analysis of observational studies. PloS One 26:e113048. Doi: 10.1371/journalpone.o113048.eCollection2014
Eschenhagen T, Erdmann E (2010): 16. Herzinsuffizienz. In: Lemmer B, Brune K (Hrsg): Pharmakotherapie – Klinische Pharmakologie, 14. Auflage, Springer, Heidelberg New York, S. 229–243
Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017: GOLD 2017 Global Strategy for the Diagnosis, Management and Prevention of COPD. Available from: http://www.goldcopd.org
Grundt C, Meier K, Grundt A, Lemmer B (2007): Evidence for an estradiol-agonistic action of nebivolol in spontaneously hypertensive rats. J Hypertens 25: 1001–1007
Hines KL, Peebles RS (2017): Management of the asthma-COPD overlap syndrome (AOCS): a review of the evidence. Curr Allergy Asthma Rep 17: 15, doi: 10.007/s11882-017-064
Hohlfeld T, Kelm M (2010): 17. Koronare Herzkrankheit. In: Lemmer B, Brune K (Hrsg): Pharmakotherapie – Klinische Pharmakologie, 14. Auflage, Springer, Heidelberg New York, S. 245–257
Hoppe UC, Erdmann E (2010): Herzinsuffizienz Update 2010 und aktuelle ESC-Leitlinien. Herz 35: 535–541
Kintscher U, Böhm M, Goss F, Kolloch R, Kreutz R, Schmieder R, Schunkert H (2014): Kommentar zur 2013-ESH/ESC-Leitlinie zum Management der arteriellen Hypertonie. Kardiologie 8:223-230
Kreutz R, Kolloch R (2010): Arterielle Hypertonie. In: Lemmer B, Brune K (Hrsg): Pharmakotherapie - Klinische Pharmakologie, 14. Auflage, Springer Verlag, Berlin Heidelberg New York, S. 197–218
Léauté-Labrèze C, Hoeger P, Mazereew-Hautier J, et al. (2015): A randomized, controlled trial of propranolol in infantile hemangioma. N Eng J Med 19:735-746
Lindholm LH, Carlberg B, Samuelsson O (2005): Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366: 1545–1553
MERIT-HF Study (1999): Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure. Lancet 353: 2001–2007
Moen MD, Wagstaff AJ (2006): Nebivolol – a review of its use in the management of hypertension and chronic heart failure. Drugs 66: 1389–1409
National Institute for Health and Care Excellence (NICE) (2011): Hypertension – Clinical management of primary hypertension in adults. Issued: August 2011. NICE clinical guideline 127: Internet: guidance.nice.org.uk/cg127
Nationale VersorgungsLeitlinie (2013): Chronische Herzinsuffizienz. http://www.leitlinien.de/nvl/herzinsuffizienz
Packer M, Coats AJS, Fowler MB, Katus HA et al (2001): Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344: 1651–1658
POISE Study Group (2008): Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial) a randomized controlled trial. Lancet 371: 1839–1847
Sackner-Bernstein J (2005): Reducing the risks of sudden death and heart failure post myocardial infarction: utility of optimized pharmacotherapy. Clin Cardiol 28 (11 Suppl 1): I19–27
Salpeter S, Ormiston T, Salpeter E, Wood-Baker R (2006): Cardioselective beta-blockers for reversible airway disease. The Cochrane Library, The Cochrane Collaboration Volume (1), 2006
Tzemos N, Lim PO, MacDonald TM (2001): Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation 104: 511–514
Wiysonge CS, Bradley HA, JV, Mayosi MB, Mbewu A, Opie LH (2012): Beta-blockers for hypertension. Cochrane Database Syst Rev. Nov 14: CD002003
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer-Verlag GmbH Germany
About this chapter
Cite this chapter
Lemmer, B. (2017). Betarezeptorenblocker. In: Schwabe, U., Paffrath, D., Ludwig, WD., Klauber, J. (eds) Arzneiverordnungs-Report 2017. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-54630-7_21
Download citation
DOI: https://doi.org/10.1007/978-3-662-54630-7_21
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-54629-1
Online ISBN: 978-3-662-54630-7
eBook Packages: Medicine (German Language)